You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOndansetron
Accession NumberDB00904  (APRD00481)
TypeSmall Molecule
GroupsApproved
Description

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
Zofran odtNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Zofraninjection2 mg/mLintramuscular; intravenousGlaxo Smith Kline Llc1991-02-04Not AvailableUs
Zofrantablet, film coated4 mgoralGlaxo Smith Kline Llc1993-02-11Not AvailableUs
Zofrantablet, film coated8 mgoralGlaxo Smith Kline Llc1993-02-11Not AvailableUs
Zofransolution4 mg/5mLoralGlaxo Smith Kline Llc1997-02-05Not AvailableUs
Zofran ODTtablet, orally disintegrating4 mgoralGlaxo Smith Kline Llc1999-03-01Not AvailableUs
Zofran ODTtablet, orally disintegrating8 mgoralGlaxo Smith Kline Llc1999-03-01Not AvailableUs
Zuplenzfilm, soluble4 mgoralPraelia Pharmaceuticals Inc2010-07-052015-11-30Us
Zuplenzfilm, soluble8 mgoralPraelia Pharmaceuticals Inc2010-07-052015-11-30Us
Zofrantablet, orally disintegrating8 mgoralREMEDYREPACK INC.2011-12-19Not AvailableUs
Zofrantablet, orally disintegrating4 mgoralCardinal Health1999-01-27Not AvailableUs
Zuplenzfilm, soluble4 mgoralGalena Biopharma, Inc.2014-10-08Not AvailableUs
Zuplenzfilm, soluble8 mgoralGalena Biopharma, Inc.2014-10-08Not AvailableUs
Zofrantablet4 mgoralGlaxosmithkline IncNot AvailableNot AvailableCanada
Zofrantablet8 mgoralGlaxosmithkline IncNot AvailableNot AvailableCanada
Zofranliquid2 mgintravenousGlaxosmithkline IncNot AvailableNot AvailableCanada
Zofranliquid4 mgoralGlaxosmithkline IncNot AvailableNot AvailableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ondansetroninjection2 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2013-05-04Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousPfizer Laboratories Div Pfizer Inc2013-05-04Not AvailableUs
Ondansetrontablet4 mgoralWest ward Pharmaceutical Corp2008-01-01Not AvailableUs
Ondansetrontablet8 mgoralWest ward Pharmaceutical Corp2008-01-01Not AvailableUs
Ondansetrontablet24 mgoralWest ward Pharmaceutical Corp2008-01-01Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest ward Pharmaceutical Corp2006-12-26Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest ward Pharmaceutical Corp2006-12-26Not AvailableUs
Ondansetrontablet, film coated4 mgoralMylan Pharmaceuticals Inc.2007-06-25Not AvailableUs
Ondansetrontablet, film coated8 mgoralMylan Pharmaceuticals Inc.2007-06-25Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralMylan Pharmaceuticals Inc.2012-09-10Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralMylan Pharmaceuticals Inc.2012-09-10Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousHospira, Inc.2007-01-19Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousHospira, Inc.2006-12-26Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousHospira, Inc.2006-12-26Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2006-12-26Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2006-12-26Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2006-12-26Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2006-11-22Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2006-11-22Not AvailableUs
Ondansetrontablet, film coated4 mgoralSandoz Inc2007-06-25Not AvailableUs
Ondansetrontablet, film coated8 mgoralSandoz Inc2007-06-25Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousSandoz Inc2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralSandoz Inc2007-08-31Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralSandoz Inc2007-08-13Not AvailableUs
Ondansetrontablet4 mgoralMajor Pharmaceuticals2008-01-01Not AvailableUs
Ondansetrontablet8 mgoralMajor Pharmaceuticals2008-01-01Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-11-19Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-11-19Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-11-19Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-11-19Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralHHS/Program Support Center/Supply Service Center2011-07-26Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralStat Rx USA2009-10-27Not AvailableUs
Ondansetronsolution4 mg/5mLoralNorth Star Rx Llc2007-11-28Not AvailableUs
Ondansetronsolution4 mg/5mLoralAtlantic Biologicals Corps2010-12-17Not AvailableUs
Ondansetronsolution4 mg/5mLoralAtlantic Biologicals Corps2010-12-17Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralRebel Distributors Corp.2007-08-13Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralAidarex Pharmaceuticals LLC2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralAidarex Pharmaceuticals LLC2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralRx Change Co.2014-11-26Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralRx Change Co.2014-12-02Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralLake Erie Medical DBA Quality Care Products LLC2010-11-10Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-07-26Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralLake Erie Medical DBA Quality Care Products LLC2007-08-31Not AvailableUs
Ondansetrontablet, film coated4 mgoralLake Erie Medical DBA Quality Care Products LLC2007-07-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralRebel Distributors Corp2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralRebel Distributors Corp2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralRebel Distributors Corp2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralRebel Distributors Corp2007-06-27Not AvailableUs
Ondansetrontablet, film coated4 mgoralSTAT Rx USA LLC2007-06-25Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralPd Rx Pharmaceuticals, Inc.2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralPd Rx Pharmaceuticals, Inc.2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralPd Rx Pharmaceuticals, Inc.2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralPd Rx Pharmaceuticals, Inc.2007-08-31Not AvailableUs
Ondansetrontablet, film coated4 mgoralActavis Inc.2007-07-27Not AvailableUs
Ondansetrontablet, film coated8 mgoralActavis Inc.2007-07-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralUnit Dose Services2007-08-02Not AvailableUs
Ondansetrontablet, film coated4 mgoralMylan Institutional Inc.2012-12-05Not AvailableUs
Ondansetrontablet, film coated8 mgoralMylan Institutional Inc.2012-12-05Not AvailableUs
Ondansetronsolution4 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2007-11-30Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2013-05-06Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2013-06-10Not AvailableUs
Ondansetrontablet, film coated4 mgoralREMEDYREPACK INC.2014-11-24Not AvailableUs
Ondansetrontablet, film coated4 mgoralREMEDYREPACK INC.2013-05-23Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2014-03-24Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2013-06-24Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2014-11-04Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2013-06-10Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralREMEDYREPACK INC.2014-10-29Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralREMEDYREPACK INC.2013-05-23Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralREMEDYREPACK INC.2013-08-21Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralREMEDYREPACK INC.2014-10-14Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscularREMEDYREPACK INC.2013-12-17Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscularREMEDYREPACK INC.2013-11-25Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscularREMEDYREPACK INC.2013-10-14Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscularREMEDYREPACK INC.2013-11-25Not AvailableUs
Ondansetroninjection, solution2 mg/mLintravenousREMEDYREPACK INC.2014-01-09Not AvailableUs
Ondansetroninjection, solution2 mg/mLintravenousREMEDYREPACK INC.2014-02-13Not AvailableUs
Ondansetronsolution4 mg/5mLoralSilarx Pharmaceuticals, Inc2011-01-27Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralPhysicians Total Care, Inc.2007-01-16Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralPhysicians Total Care, Inc.2008-05-08Not AvailableUs
Ondansetroninjection2 mg/mLintravenousPhysicians Total Care, Inc.2008-05-08Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralDispensing Solutions, Inc.2007-06-27Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousAuro Medics Pharma Llc2012-12-21Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousAuro Medics Pharma Llc2012-12-21Not AvailableUs
Ondansetrontablet, film coated4 mgoralCardinal Health2007-06-25Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousCardinal Health2010-11-19Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousCardinal Health2010-11-19Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousCardinal Health2006-12-26Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousCardinal Health2006-12-26Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralCardinal Health2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralCardinal Health2007-06-27Not AvailableUs
Ondansetrontablet, film coated4 mgoralCardinal Health2007-07-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralCardinal Health2007-08-02Not AvailableUs
Ondansetrontablet, film coated4 mgoralCardinal Health2012-12-05Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralCardinal Health2007-08-31Not AvailableUs
Ondansetrontablet, film coated8 mgoralCardinal Health2012-12-05Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousCardinal Health2012-12-21Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralPd Rx Pharmaceuticals, Inc.2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralCitron Pharma LLC2010-04-12Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralCitron Pharma LLC2010-04-12Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralClinical Solutions Wholesale2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralClinical Solutions Wholesale2007-08-02Not AvailableUs
Ondansetrontablet, film coated4 mgoralClinical Solutions Wholesale2007-06-25Not AvailableUs
Ondansetrontablet, film coated8 mgoralClinical Solutions Wholesale2007-06-25Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralClinical Solutions Wholesale2007-08-31Not AvailableUs
Ondansetronsolution4 mg/5mLoralApotex Corp2008-03-13Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralSt Marys Medical Park Pharmacy2014-05-23Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2015-01-12Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralREMEDYREPACK INC.2014-11-13Not AvailableUs
Ondansetrontablet, film coated4 mgoralDIRECT RX2014-01-01Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralDIRECT RX2014-01-01Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralDIRECT RX2014-01-01Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralSun Pharmaceutical Industries Limited2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralSun Pharmaceutical Industries Limited2007-08-02Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralProficient Rx2007-08-31Not AvailableUs
Ondansetrontablet, film coated8 mgoralProficient Rx LP2007-06-25Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralProficient Rx LP2007-06-27Not AvailableUs
Ondansetrontablet, film coated4 mgoralProficient Rx LP2007-06-25Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralProficient Rx LP2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralRnabaxy Pharmaceuticals Inc.2012-01-10Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralRnabaxy Pharmaceuticals Inc.2012-01-10Not AvailableUs
Ondansetrontablet, film coated4 mgoralRanbaxy Pharmaceuticals Inc.2007-06-25Not AvailableUs
Ondansetrontablet, film coated8 mgoralRanbaxy Pharmaceuticals Inc.2007-06-25Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2009-11-18Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2009-11-18Not AvailableUs
Ondansetron Hydrochloridetablet, orally disintegrating4 mgoralbryant ranch prepack2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralbryant ranch prepack2007-08-02Not AvailableUs
Ondansetrontablet, film coated4 mgoralbryant ranch prepack2007-06-25Not AvailableUs
Ondansetrontablet, film coated4 mgoralbryant ranch prepack2007-06-25Not AvailableUs
Ondansetronsolution4 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2010-12-17Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousThe Medicines Company2009-11-18Not AvailableUs
Ondansetroninjection2 mg/mLintramuscular; intravenousThe Medicines Company2009-11-18Not AvailableUs
Ondansetronsolution4 mg/5mLoralAurobindo Pharma Limited2007-11-28Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralAurobindo Pharma Limited2010-04-12Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralAurobindo Pharma Limited2010-04-12Not AvailableUs
Ondansetroninjection, solution2 mg/mLintramuscular; intravenousQilu Pharmaceutical Co., Ltd.2014-09-08Not AvailableUs
Ondansetron Hydrochloridesolution2 mg/mLintramuscular; intravenousMylan Institutional LLC2014-12-29Not AvailableUs
Ondansetron Hydrochloridesolution2 mg/mLintramuscular; intravenousMylan Institutional LLC2014-12-29Not AvailableUs
Ondansetrontablet, film coated4 mgoralAscend Laboratories, LLC2007-06-25Not AvailableUs
Ondansetrontablet, film coated8 mgoralAscend Laboratories, LLC2007-06-25Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralBlue Point Laboratories2014-03-13Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralBlue Point Laboratories2014-03-13Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralDispensing Solutions, Inc.2007-06-27Not AvailableUs
Ondansetrontablet, film coated4 mgoralGlenmark Generics Inc., USA2007-06-25Not AvailableUs
Ondansetrontablet, film coated8 mgoralGlenmark Generics Inc., USA2007-06-25Not AvailableUs
Ondansetrontablet, film coated24 mgoralGlenmark Generics Inc., USA2007-06-25Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralGlenmark Generics Inc., USA2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralGlenmark Generics Inc., USA2007-06-27Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralPreferred Pharmaceuticals, Inc.2013-08-27Not AvailableUs
Ondansetrontablet, orally disintegrating4 mgoralPreferred Pharmaceuticals, Inc.2013-07-24Not AvailableUs
Ondansetrontablet, film coated8 mgoralPreferred Pharmaceuticals, Inc.2012-07-27Not AvailableUs
Ondansetrontablet, orally disintegrating8 mgoralPreferred Pharmaceuticals, Inc2012-02-14Not AvailableUs
Ondansetrontablet, film coated8 mgoralLife Line Home Care Services, Inc.2007-06-25Not AvailableUs
Ondansetroninjection, solution4 mg/2mLintravenousBD Rx Inc.2013-08-23Not AvailableUs
Ondansetrontablet8 mgoralPro Doc LimiteeNot AvailableNot AvailableCanada
Ondansetrontablet4 mgoralSanis Health IncNot AvailableNot AvailableCanada
Ondansetrontablet8 mgoralSanis Health IncNot AvailableNot AvailableCanada
Ondansetronsolution4 mgoralAa Pharma IncNot AvailableNot AvailableCanada
Over the Counter ProductsNot Available
International Brands
NameCompany
ZophrenNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ondansetron hydrochloride dihydrate
ThumbNot applicableDBSALT000921
Categories
CAS number99614-02-5
WeightAverage: 293.363
Monoisotopic: 293.152812245
Chemical FormulaC18H19N3O
InChI KeyFELGMEQIXOGIFQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
IUPAC Name
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one
SMILES
CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassCarbazoles
Direct ParentCarbazoles
Alternative Parents
Substituents
  • Carbazole
  • Indole
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzenoid
  • Substituted pyrrole
  • N-substituted imidazole
  • N-methylpyrrole
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrole
  • Imidazole
  • Azole
  • Ketone
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting.
PharmacodynamicsOndansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.
Mechanism of actionOndansetron is a selective serotonin 5-HT3 receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
AbsorptionOndansetron is well absorbed after oral administration and undergoes limited first-pass metabolism.
Volume of distributionNot Available
Protein binding70%-76% (Plasma protein binding)
Metabolism

Hepatic

Route of eliminationNot Available
Half life5.7 hours
Clearance
  • 0.38 L/h/kg [Normal Adult Volunteers (19-40 yrs)]
  • 0.32 L/h/kg [Normal Adult Volunteers (61-74 yrs)]
  • 0.26 L/h/kg [Normal Adult Volunteers (>=75 yrs)]
ToxicityLow blood pressure and fainting, sudden blindness, severe constipation
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9882
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7019
P-glycoprotein inhibitor IInhibitor0.5833
P-glycoprotein inhibitor IIInhibitor0.8807
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7456
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.647
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 substrateNon-inhibitor0.9071
CYP450 2D6 substrateInhibitor0.8932
CYP450 2C19 substrateNon-inhibitor0.9026
CYP450 3A4 substrateNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5954
Ames testNon AMES toxic0.5463
CarcinogenicityNon-carcinogens0.9676
BiodegradationNot ready biodegradable0.9884
Rat acute toxicity2.4555 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7054
hERG inhibition (predictor II)Inhibitor0.7926
Pharmacoeconomics
Manufacturers
  • Par pharmaceutical
  • Aurobindo pharma ltd
  • Barr laboratories inc
  • Glenmark generics ltd
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Akorn strides llc
  • Apotex inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Emcure pharmaceuticals ltd
  • Gland pharma ltd
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Lannett holdings inc
  • Luitpold pharmaceuticals inc
  • Pharmaforce inc
  • Pliva hrvatska doo
  • Sandoz canada inc
  • Spectrum pharmaceuticals
  • Wockhardt ltd
  • Bedford laboratories
  • Claris lifesciences ltd
  • Teva parenteral medicines inc
  • Baxter healthcare corp
  • Apotex inc richmond hill
  • Taro pharmaceuticals ireland ltd
  • Roxane laboratories inc
  • Taro pharmaceutical industries ltd
  • Dr reddys laboratories ltd
  • Natco pharma ltd
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Film, solubleoral4 mg
Film, solubleoral8 mg
Injectionintramuscular; intravenous2 mg/mL
Injectionintravenous2 mg/mL
Injection, solutionintramuscular2 mg/mL
Injection, solutionintramuscular; intravenous2 mg/mL
Injection, solutionintravenous2 mg/mL
Injection, solutionintravenous4 mg/2mL
Liquidintravenous2 mg
Liquidoral4 mg
Solutionintramuscular; intravenous2 mg/mL
Solutionoral4 mg
Solutionoral4 mg/5mL
Tabletoral24 mg
Tabletoral4 mg
Tabletoral8 mg
Tablet, film coatedoral24 mg
Tablet, film coatedoral4 mg
Tablet, film coatedoral8 mg
Tablet, orally disintegratingoral4 mg
Tablet, orally disintegratingoral8 mg
Prices
Unit descriptionCostUnit
Ondansetron 30 8 mg Dispersible Tablet Box1158.51USD box
Zofran ODT 30 4 mg Dispersible Tablet Box782.26USD box
Ondansetron 30 4 mg Dispersible Tablet Box695.53USD box
Ondansetron hcl powder177.0USD g
Ondansetron hcl 24 mg tablet105.5USD tablet
Zofran 8 mg tablet45.16USD tablet
Zofran odt 8 mg tablet41.76USD tablet
Ondansetron hcl 8 mg tablet40.75USD tablet
Ondansetron odt 8 mg tablet37.13USD tablet
Zofran 4 mg tablet27.11USD tablet
Ondansetron hcl 4 mg tablet25.07USD tablet
Zofran odt 4 mg tablet25.07USD tablet
Zofran 8 mg Tablet23.02USD tablet
Zofran Odt 8 mg Disintegrating Tablet22.49USD tablet
Ondansetron odt 4 mg tablet22.3USD tablet
Zofran 4 mg Tablet15.09USD tablet
Zofran Odt 4 mg Disintegrating Tablet14.74USD tablet
Zofran 2 mg/ml vial12.82USD ml
Zofran 4 mg/2 ml vial12.82USD ml
Apo-Ondansetron 8 mg Tablet12.06USD tablet
Co Ondansetron 8 mg Tablet12.06USD tablet
Jamp-Ondansetron 8 mg Tablet12.06USD tablet
Mint-Ondansetron 8 mg Tablet12.06USD tablet
Mylan-Ondansetron 8 mg Tablet12.06USD tablet
Novo-Ondansetron 8 mg Tablet12.06USD tablet
Ondansetron-Odan 8 mg Tablet12.06USD tablet
Phl-Ondansetron 8 mg Tablet12.06USD tablet
Pms-Ondansetron 8 mg Tablet12.06USD tablet
Ran-Ondansetron 8 mg Tablet12.06USD tablet
Ratio-Ondansetron 8 mg Tablet12.06USD tablet
Sandoz Ondansetron 8 mg Tablet12.06USD tablet
Zofran 2 mg/ml11.12USD ml
Apo-Ondansetron 4 mg Tablet7.9USD tablet
Co Ondansetron 4 mg Tablet7.9USD tablet
Jamp-Ondansetron 4 mg Tablet7.9USD tablet
Mint-Ondansetron 4 mg Tablet7.9USD tablet
Mylan-Ondansetron 4 mg Tablet7.9USD tablet
Novo-Ondansetron 4 mg Tablet7.9USD tablet
Ondansetron-Odan 4 mg Tablet7.9USD tablet
Phl-Ondansetron 4 mg Tablet7.9USD tablet
Pms-Ondansetron 4 mg Tablet7.9USD tablet
Ran-Ondansetron 4 mg Tablet7.9USD tablet
Ratio-Ondansetron 4 mg Tablet7.9USD tablet
Sandoz Ondansetron 4 mg Tablet7.9USD tablet
Ondansetron (Preservative Free) 2 mg/ml6.23USD ml
Ondansetron (Preserved) 2 mg/ml6.23USD ml
Ondansetron (Unpreserved) 2 mg/ml6.23USD ml
Ondansetron (With Preservative) 2 mg/ml6.23USD ml
Ondansetron Omega (Preservative Free) 2 mg/ml6.23USD ml
Ondansetron Omega (With Preservative) 2 mg/ml6.23USD ml
Ondansetron hcl 4 mg/2 ml vial3.13USD ml
Zofran 0.8 mg/ml Solution2.3USD ml
Apo-Ondansetron 0.8 mg/ml Solution1.53USD ml
Ondansetron 32 mg/50 ml bag0.86USD ml
Ondansetron hcl 32 mg/50 ml bg0.42USD ml
Ondansetron 40 mg/20 ml vial0.17USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada22056002000-05-302015-11-20
United States53446581994-09-062011-09-06
United States58542701996-05-202016-05-20
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.248 mg/mLALOGPS
logP2.56ALOGPS
logP2.35ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)15.39ChemAxon
pKa (Strongest Basic)7.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area39.82 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity86.78 m3·mol-1ChemAxon
Polarizability33.16 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra1D NMR2D NMR
References
Synthesis Reference

Peter Bod, Kalman Harsanyi, Ferenc Trischler, Eva Fekecs, Attila Csehi, Bela Hegedus, Eva Mersich nee Donat, Gyorgyi Szabo nee Komlosi, Erika Horvath nee Sziki, “Process for preparing ondansetron.” U.S. Patent US5478949, issued September, 1990.

US5478949
General Reference
  1. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. Pubmed
  2. Yilmaz HL, Yildizdas RD, Sertdemir Y: Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children—a double-blind randomized study. Aliment Pharmacol Ther. 2010 Jan;31(1):82-91. Epub . Pubmed
  3. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. Pubmed
  4. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. Pubmed
External Links
ATC CodesA04AA01
AHFS Codes
  • 56:22.20
PDB EntriesNot Available
FDA labelDownload (126 KB)
MSDSDownload (53.2 KB)
Interactions
Drug Interactions
Drug
AsenapineAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
CrizotinibConcurrent use with crizotinib may decrease QTc interval. Consider alternative therapy.
EzogabineConcurrent use of ezogabine and ondansetron can increase QTc interval. Consider alternate therapy.
IndacaterolBoth indacaterol and ondansetron prolong the QT interval. Consider alternate therapy.
PazopanibAdditive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
TelavancinAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
Food Interactions
  • Take without regard to meals.

Targets

1. 5-hydroxytryptamine receptor 3A

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 3A P46098 Details

References:

  1. Artaiz I, Zazpe A, Del Rio J: Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice. Behav Pharmacol. 1998 Mar;9(2):103-12. Pubmed
  2. Fortuno A, Ballaz S, Del Rio J, Barber A: CCK-mediated response in the activation of 5-HT receptor types in the guinea-pig ileum. J Physiol Biochem. 1999 Jun;55(2):85-92. Pubmed
  3. Llacer JM, Gallardo V, Delgado R, Parraga J, Martin D, Ruiz MA: X-ray diffraction and electron microscopy in the polymorphism study of ondansetron hydrochloride. Drug Dev Ind Pharm. 2001 Oct;27(9):899-908. Pubmed
  4. Carvalho F, Macedo D, Bandeira I, Maldonado I, Salles L, Azevedo MF, Rocha MA Jr, Fregoneze JB, De Castro-e-Silva E: Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats. Horm Metab Res. 2002 Feb;34(2):55-61. Pubmed
  5. Arcioni R, della Rocca M, Romano S, Romano R, Pietropaoli P, Gasparetto A: Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT spinal receptor involvement in acute pain in humans. Anesth Analg. 2002 Jun;94(6):1553-7, table of contents. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  7. Gallardo Lara V, Gallardo ML, Morales Hernandez ME, Ruiz Martinez MA: Ondansetron: design and development of oral pharmaceutical suspensions. Pharmazie. 2009 Feb;64(2):90-3. Pubmed
  8. Mohan KC, Ravikumar K: Ondansetron hydrochloride: a competitive serotonin 5-HT3 receptor blocker. Acta Crystallogr C. 1995 Dec 15;51 ( Pt 12):2627-9. Pubmed
  9. Dimitrov DH: Effect of Ondansetron, a 5-HT Receptor Antagonist, on Fatigue in 2 Veterans With Hepatitis C. Prim Care Companion J Clin Psychiatry. 2009;11(6):366-7. Pubmed
  10. Szajewska H, Gieruszczak-Bialek D, Dylag M: Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007 Feb 15;25(4):393-400. Pubmed
  11. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. Pubmed
  12. Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. Pubmed
  13. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. Pubmed

2. 5-hydroxytryptamine receptor 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 4 Q13639 Details

References:

  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. Pubmed

3. Mu-type opioid receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
Mu-type opioid receptor P35372 Details

References:

  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. Pubmed

4. 5-hydroxytryptamine receptor 1A

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1A P08908 Details

References:

  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. Pubmed

5. 5-hydroxytryptamine receptor 1B

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1B P28222 Details

References:

  1. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990 Jun 12;188(6):301-12. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8. Epub 2005 Sep 26. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

5. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

6. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2E1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 04, 2013 13:24